Cogent Biosciences, Inc. Research and Development Expense
Cogent Biosciences, Inc. (COGT) reported Research and Development Expense of $70.81 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-10
- Cogent Biosciences, Inc. research and development expense for the quarter ending 2026-06-30 was $70.81M, a 13.84% increase year-over-year.
- Cogent Biosciences, Inc. research and development expense for the quarter ending 2026-03-31 was $75.36M, a 19.57% increase year-over-year.
- Cogent Biosciences, Inc. research and development expense for the quarter ending 2025-12-31 was $75.56M, a 21.78% increase year-over-year.
- Cogent Biosciences, Inc. research and development expense for the quarter ending 2025-09-30 was $68.99M, a 8.45% increase year-over-year.
- Cogent Biosciences, Inc. research and development expense for fiscal 2025 was $269.78M, a 15.96% increase from fiscal 2024.
- Cogent Biosciences, Inc. research and development expense for fiscal 2024 was $232.66M, a 33.90% increase from fiscal 2023.
- Cogent Biosciences, Inc. research and development expense for fiscal 2023 was $173.75M, a 42.86% increase from fiscal 2022.
- Cogent Biosciences, Inc. research and development expense for fiscal 2022 was $121.63M, a 117.53% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $70.81M 10-Q · filed 2026-08-10 | $146.18M 10-Q · filed 2026-08-10 | $221.74M derived: sum of 3 quarters · filed 2026-08-10 | $290.72M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $75.36M 10-Q · filed 2026-05-05 | $150.92M derived: sum of 2 quarters · filed 2026-05-05 | $219.91M derived: sum of 3 quarters · filed 2026-05-05 | $282.12M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $75.56M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $144.55M derived: sum of 2 quarters · filed 2026-02-17 | $206.75M derived: sum of 3 quarters · filed 2026-08-10 | $269.78M 10-K · filed 2026-02-17 |
| 2025-09-30 | $68.99M 10-Q · filed 2025-11-07 | $131.19M derived: sum of 2 quarters · filed 2026-08-10 | $194.22M 10-Q · filed 2025-11-07 | $256.27M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $62.20M 10-Q · filed 2026-08-10 | $125.23M 10-Q · filed 2026-08-10 | $187.28M derived: sum of 3 quarters · filed 2026-08-10 | $250.89M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $63.03M 10-Q · filed 2026-05-05 | $125.07M derived: sum of 2 quarters · filed 2026-05-05 | $188.69M derived: sum of 3 quarters · filed 2026-05-05 | $242.98M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $62.05M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $125.66M derived: sum of 2 quarters · filed 2026-02-17 | $179.95M derived: sum of 3 quarters · filed 2026-02-17 | $232.66M 10-K · filed 2026-02-17 |
| 2024-09-30 | $63.61M 10-Q · filed 2025-11-07 | $117.91M derived: sum of 2 quarters · filed 2025-11-07 | $170.61M 10-Q · filed 2025-11-07 | $219.33M derived: sum of 4 quarters · filed 2026-02-17 |
| 2024-06-30 | $54.29M 10-Q · filed 2025-08-05 | $107.00M 10-Q · filed 2025-08-05 | $155.72M derived: sum of 3 quarters · filed 2026-02-17 | $205.84M derived: sum of 4 quarters · filed 2026-02-17 |
| 2024-03-31 | $52.70M 10-Q · filed 2025-05-06 | $101.42M derived: sum of 2 quarters · filed 2026-02-17 | $151.55M derived: sum of 3 quarters · filed 2026-02-17 | $190.42M derived: sum of 4 quarters · filed 2026-02-17 |
| 2023-12-31 | $48.72M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $98.85M derived: sum of 2 quarters · filed 2026-02-17 | $137.72M derived: sum of 3 quarters · filed 2026-02-17 | $173.75M 10-K · filed 2026-02-17 |
| 2023-09-30 | $50.13M 10-Q · filed 2024-11-12 | $89.00M derived: sum of 2 quarters · filed 2024-11-12 | $125.04M 10-Q · filed 2024-11-12 | $161.78M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | $38.87M 10-Q · filed 2024-08-06 | $74.91M 10-Q · filed 2024-08-06 | $111.65M derived: sum of 3 quarters · filed 2025-02-25 | $141.59M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-03-31 | $36.04M 10-Q · filed 2024-05-07 | $72.78M derived: sum of 2 quarters · filed 2025-02-25 | $102.72M derived: sum of 3 quarters · filed 2025-02-25 | $132.19M derived: sum of 4 quarters · filed 2025-02-25 |
| 2022-12-31 | $36.74M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $66.68M derived: sum of 2 quarters · filed 2025-02-25 | $96.16M derived: sum of 3 quarters · filed 2025-02-25 | $121.63M 10-K · filed 2025-02-25 |
| 2022-09-30 | $29.94M 10-Q · filed 2023-11-07 | $59.41M derived: sum of 2 quarters · filed 2023-11-07 | $84.89M 10-Q · filed 2023-11-07 | $105.40M derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-06-30 | $29.48M 10-Q · filed 2023-08-08 | $54.95M 10-Q · filed 2023-08-08 | $75.46M derived: sum of 3 quarters · filed 2024-02-26 | $90.26M derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-03-31 | $25.47M 10-Q · filed 2023-05-09 | $45.98M derived: sum of 2 quarters · filed 2024-02-26 | $60.78M derived: sum of 3 quarters · filed 2024-02-26 | $73.17M derived: sum of 4 quarters · filed 2024-02-26 |
| 2021-12-31 | $20.51M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | $35.31M derived: sum of 2 quarters · filed 2024-02-26 | $47.70M derived: sum of 3 quarters · filed 2024-02-26 | $55.91M 10-K · filed 2024-02-26 |
| 2021-09-30 | $14.80M 10-Q · filed 2022-11-14 | $27.19M derived: sum of 2 quarters · filed 2022-11-14 | $35.40M 10-Q · filed 2022-11-14 | $41.51M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $12.39M 10-Q · filed 2022-08-09 | $20.60M 10-Q · filed 2022-08-09 | $26.71M derived: sum of 3 quarters · filed 2022-08-09 | $31.71M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | $8.21M 10-Q · filed 2022-05-10 | $14.32M derived: sum of 2 quarters · filed 2022-05-10 | $19.32M derived: sum of 3 quarters · filed 2022-05-10 | $24.45M derived: sum of 4 quarters · filed 2022-05-10 |
| 2020-12-31 | $6.11M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | $11.11M derived: sum of 2 quarters · filed 2022-03-15 | $16.24M derived: sum of 3 quarters · filed 2022-03-15 | $25.74M 10-K · filed 2022-03-15 |
| 2020-09-30 | $5.00M 10-Q · filed 2021-11-10 | $10.13M derived: sum of 2 quarters · filed 2021-11-10 | $19.63M 10-Q · filed 2021-11-10 | $29.98M derived: sum of 4 quarters · filed 2021-11-10 |
| 2020-06-30 | $5.13M 10-Q · filed 2021-08-16 | $14.63M 10-Q · filed 2021-08-16 | $24.98M derived: sum of 3 quarters · filed 2021-08-16 | $35.32M derived: sum of 4 quarters · filed 2021-08-16 |
| 2020-03-31 | $9.50M 10-Q · filed 2021-05-12 | $19.85M derived: sum of 2 quarters · filed 2021-05-12 | $30.19M derived: sum of 3 quarters · filed 2021-05-12 | $40.80M derived: sum of 4 quarters · filed 2021-05-12 |
| 2019-12-31 | $10.35M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-16 | $20.69M derived: sum of 2 quarters · filed 2021-03-16 | $31.31M derived: sum of 3 quarters · filed 2021-03-16 | $43.71M 10-K · filed 2021-03-16 |
| 2019-09-30 | $10.34M 10-Q · filed 2020-11-09 | $20.95M derived: sum of 2 quarters · filed 2020-11-09 | $33.35M 10-Q · filed 2020-11-09 | $44.12M derived: sum of 4 quarters · filed 2020-11-09 |
| 2019-06-30 | $10.62M 10-Q · filed 2020-08-11 | $23.02M 10-Q · filed 2020-08-11 | $33.78M derived: sum of 3 quarters · filed 2020-08-11 | $44.04M derived: sum of 4 quarters · filed 2020-08-11 |
| 2019-03-31 | $12.40M 10-Q · filed 2020-05-11 | $23.17M derived: sum of 2 quarters · filed 2020-05-11 | $33.42M derived: sum of 3 quarters · filed 2020-05-11 | $42.55M derived: sum of 4 quarters · filed 2020-05-11 |
| 2018-12-31 | $10.77M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-26 | $21.02M derived: sum of 2 quarters · filed 2020-03-26 | $30.14M derived: sum of 3 quarters · filed 2020-03-26 | $38.28M 10-K · filed 2020-03-26 |
| 2018-09-30 | $10.25M 10-Q · filed 2019-11-12 | $19.38M derived: sum of 2 quarters · filed 2019-11-12 | $27.52M 10-Q · filed 2019-11-12 | $35.08M derived: sum of 4 quarters · filed 2019-11-12 |
| 2018-06-30 | $9.13M 10-Q · filed 2019-08-12 | $17.27M 10-Q · filed 2019-08-12 | $24.83M derived: sum of 3 quarters · filed 2019-08-12 | $33.01M derived: sum of 4 quarters · filed 2019-08-12 |
| 2018-03-31 | $8.14M 10-Q · filed 2019-05-13 | $15.70M derived: sum of 2 quarters · filed 2019-05-13 | $23.88M derived: sum of 3 quarters · filed 2019-05-13 | $31.02M derived: sum of 4 quarters · filed 2019-05-13 |
| 2017-12-31 | $7.56M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-28 | $15.74M derived: sum of 2 quarters · filed 2019-03-28 | $22.88M derived: sum of 3 quarters · filed 2019-03-28 | $29.83M 10-K · filed 2019-03-28 |
| 2017-09-30 | $8.18M 10-Q · filed 2018-11-13 | $15.32M derived: sum of 2 quarters · filed 2018-11-13 | $22.27M 10-Q · filed 2018-11-13 | |
| 2017-06-30 | $7.14M 10-Q · filed 2018-08-13 | $14.09M 10-Q · filed 2018-08-13 | ||
| 2017-03-31 | $6.95M 10-Q · filed 2018-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |